Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases
February 7th, 2010 Posted by: admin
Publication year: 2010
Source: The American Journal of Cardiology, In Press, Corrected Proof, Available online 5 February 2010
Steven G., Chrysant
Clinical and experimental studies have shown that the initial suppression of angiotensin II after the administration of angiotensin-converting enzyme (ACE) inhibitors is later reversed and returns almost to pretreatment levels. This raised the hypothesis of the “escape phenomenon,” which was strengthened by the discovery that angiotensin II can also be generated through non-ACEs. Therefore, the addition of angiotensin receptor blockers to ACE inhibitors would produce additional benefits by blocking all angiotensin II at the angiotensin II receptor type 1 level and in addition allowing angiotensin II to stimulate the unoccupied angiotensin II receptor type 2, causing additional vasodilation and antiremodeling…
Similar Posts:
- Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
- Are There Effects of Renin–Angiotensin System Antagonists Beyond Blood Pressure Control?
- Angiotensin receptors in the eyes of arterial hypertensive rats
- Renin–Angiotensin System Blockade and Cardiovascular and Renal Protection
- Telmisartan in High-Risk Cardiovascular Patients
- Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension
- Pharmaceutical Research: Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs
- Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease
- Purification, crystallization and preliminary data analysis of ligand–receptor complexes of growth and differentiation factor 5 (GDF5) and BMP receptor IB (BRIB)
- Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])